Shares of T2 Biosystems Inc. (NASDAQ:TTOO) traded down 4.6% on Tuesday . The company traded as low as $4.97 and last traded at $5.03, with a volume of 121,766 shares trading hands. The stock had previously closed at $5.27.

A number of analysts have weighed in on the stock. WBB Securities upgraded shares of T2 Biosystems from a “buy” rating to a “strong-buy” rating and raised their target price for the company from $11.00 to $12.00 in a research report on Wednesday. Leerink Swann restated a “buy” rating on shares of T2 Biosystems in a research report on Sunday, July 10th. Cantor Fitzgerald restated a “buy” rating on shares of T2 Biosystems in a research report on Saturday, July 9th. Janney Montgomery Scott restated a “hold” rating on shares of T2 Biosystems in a research report on Saturday, July 9th. Finally, BTIG Research lowered shares of T2 Biosystems from a “buy” rating to a “sell” rating and cut their target price for the company from $12.00 to $4.00 in a research report on Friday, July 8th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. T2 Biosystems currently has a consensus rating of “Hold” and an average target price of $11.03.

The firm’s market capitalization is $140.36 million. The stock’s 50-day moving average is $7.71 and its 200-day moving average is $8.66.

T2 Biosystems (NASDAQ:TTOO) last posted its earnings results on Monday, May 2nd. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.54) by $0.01. During the same quarter last year, the firm posted ($0.53) EPS. The company had revenue of $1.10 million for the quarter. The firm’s revenue was up 485.1% on a year-over-year basis. On average, analysts forecast that T2 Biosystems Inc. will post ($2.17) EPS for the current fiscal year.

In related news, SVP Rahul Dhanda sold 3,589 shares of the company’s stock in a transaction that occurred on Thursday, June 30th. The shares were sold at an average price of $8.16, for a total transaction of $29,286.24. Following the sale, the senior vice president now owns 3,589 shares of the company’s stock, valued at approximately $29,286.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

An institutional investor recently raised its position in T2 Biosystems stock. Aisling Capital LLC increased its position in T2 Biosystems Inc. (NASDAQ:TTOO) by 12.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,830,992 shares of the company’s stock after buying an additional 307,692 shares during the period. T2 Biosystems makes up about 5.3% of Aisling Capital LLC’s portfolio, making the stock its 6th largest position. Aisling Capital LLC owned approximately 13.89% of T2 Biosystems worth $30,971,000 at the end of the most recent reporting period.

T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.